ES2530776T3 - Derivados de fosfolípidos y proceso para su producción - Google Patents

Derivados de fosfolípidos y proceso para su producción Download PDF

Info

Publication number
ES2530776T3
ES2530776T3 ES03778894T ES03778894T ES2530776T3 ES 2530776 T3 ES2530776 T3 ES 2530776T3 ES 03778894 T ES03778894 T ES 03778894T ES 03778894 T ES03778894 T ES 03778894T ES 2530776 T3 ES2530776 T3 ES 2530776T3
Authority
ES
Spain
Prior art keywords
production
symbol
satisfy
independently
phospholipid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03778894T
Other languages
English (en)
Inventor
Kazuhiro Kubo
Chika Itoh
Syunsuke Ohhashi
Tohru Yasukohchi
Yusuke Ohkawa
Hiroshi Kikuchi
Norio Suzuki
Miho Takahashi
Hitoshi Yamauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOF Corp
Original Assignee
NOF Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOF Corp filed Critical NOF Corp
Application granted granted Critical
Publication of ES2530776T3 publication Critical patent/ES2530776T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
    • C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/34—Oligomeric, e.g. cyclic oligomeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Un derivado de fosfolípido representado por la siguiente fórmula (1):**Fórmula** en donde [PG]k representa un residuo de poliglicerina que tiene un grado de polimerización de k, en donde k es de 2 a 50, R1CO y R2CO representan independientemente un grupo acilo que tiene de 8 a 22 átomos de carbono, el símbolo "a" representa independientemente un número entero de 0 a 5, el símbolo "b" representa independientemente 0 o 1, M representa un átomo de hidrógeno, un átomo de metal alcalino, un amonio, o un amonio orgánico, y k1, k2 y k3 representan números que satisfacen las siguientes condiciones: 1 <= k1 <= (k+2)/2, 0 <= k2, k1 + k2 + k3 >= k + 2, y k1, k2 y k3 satisfacen 8 <= k1 + k2 + k3 <= 52.
ES03778894T 2003-01-06 2003-12-12 Derivados de fosfolípidos y proceso para su producción Expired - Lifetime ES2530776T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003000330 2003-01-06
PCT/JP2003/015969 WO2004060899A1 (ja) 2003-01-06 2003-12-12 リン脂質誘導体及びその製造方法

Publications (1)

Publication Number Publication Date
ES2530776T3 true ES2530776T3 (es) 2015-03-05

Family

ID=32708767

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03778894T Expired - Lifetime ES2530776T3 (es) 2003-01-06 2003-12-12 Derivados de fosfolípidos y proceso para su producción

Country Status (9)

Country Link
US (1) US7524981B2 (es)
EP (1) EP1591447B1 (es)
JP (1) JP4403303B2 (es)
KR (1) KR101007828B1 (es)
CN (1) CN100339382C (es)
AU (1) AU2003289070A1 (es)
CA (1) CA2513144C (es)
ES (1) ES2530776T3 (es)
WO (1) WO2004060899A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220917A1 (en) 2002-03-29 2003-10-13 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
AU2003266714A1 (en) 2002-09-30 2004-04-19 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
WO2004083219A1 (ja) 2003-03-20 2004-09-30 Nof Corporation リン脂質誘導体
WO2011059073A1 (ja) 2009-11-13 2011-05-19 日油株式会社 リン脂質誘導体およびｐＨ応答性リポソーム
EP2616519B1 (en) * 2010-09-14 2018-01-03 Empire Technology Development LLC Activated ph control for protein glues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
JPH0651109B2 (ja) 1987-03-09 1994-07-06 第一製薬株式会社 脂質膜構造体
JP2676854B2 (ja) 1988-12-16 1997-11-17 日本油脂株式会社 ポリオキシアルキレン不飽和エーテルーマレイン酸エステル共重合体およびその用途
JPH06228012A (ja) 1993-01-29 1994-08-16 Dai Ichi Seiyaku Co Ltd リポソーム製剤
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3620059B2 (ja) 1994-03-04 2005-02-16 日本油脂株式会社 反応性小胞体、形成剤および機能性物質固定化小胞体
JP3480033B2 (ja) 1994-03-31 2003-12-15 日本油脂株式会社 ホスホリルコリン基又はその誘導体基含有共重合体、その製造法及び抗血栓性材料
JPH09255740A (ja) 1996-03-26 1997-09-30 Nof Corp 三元共重合体
DE59805997D1 (de) 1997-08-18 2002-11-21 Max Planck Gesellschaft Phospholipidanaloge verbindungen
GB9717905D0 (en) 1997-08-22 1997-10-29 Univ Aston Lipid-containing compositions and uses thereof
DE19835611A1 (de) 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
CA2352178A1 (en) 1998-12-08 2000-06-15 Mathew Louis Steven Leigh Phospholipid compositions
AU6105300A (en) 1999-07-16 2001-02-05 Purdue Research Foundation Vinyl ether lipids with cleavable hydrophilic headgroups
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
AU2003220917A1 (en) 2002-03-29 2003-10-13 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
AU2003266714A1 (en) 2002-09-30 2004-04-19 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
WO2004083219A1 (ja) 2003-03-20 2004-09-30 Nof Corporation リン脂質誘導体

Also Published As

Publication number Publication date
CA2513144A1 (en) 2004-07-22
EP1591447B1 (en) 2014-11-26
JPWO2004060899A1 (ja) 2006-05-11
US7524981B2 (en) 2009-04-28
CN100339382C (zh) 2007-09-26
KR101007828B1 (ko) 2011-01-13
EP1591447A1 (en) 2005-11-02
KR20050097931A (ko) 2005-10-10
AU2003289070A8 (en) 2004-07-29
CA2513144C (en) 2012-03-13
WO2004060899A1 (ja) 2004-07-22
US20060210618A1 (en) 2006-09-21
EP1591447A4 (en) 2009-11-11
AU2003289070A1 (en) 2004-07-29
JP4403303B2 (ja) 2010-01-27
CN1735624A (zh) 2006-02-15

Similar Documents

Publication Publication Date Title
NZ601567A (en) Process for production of delta-9-tetrahydrocannabinol
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
PL358428A1 (en) 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
CY1108398T1 (el) Διαδικασια και ενδιαμεσα για την παραγωγη 7-υποκατεστημενων αντιοιστρογονων
BR0211704A (pt) Processo para recuperar energia a partir de um gás
CR8360A (es) 1,3 dimetilbutilcarboxanilidas
EA200100533A1 (ru) Производные эритромицина, способ их получения и их применение в качестве лекарственных средств
EP2298733A3 (en) Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GT200300284A (es) Derivados de 3h-quinazolin-4-ona
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
ES2530776T3 (es) Derivados de fosfolípidos y proceso para su producción
DE60229054D1 (de) Synthese von zyklopentadien derivaten
CO5550494A2 (es) Derivados de diamina, proceso para producir los derivados de diamina, y fungicidas que contienen los derivados de diamina como ingrediente activo
DK1127886T3 (da) Syntese af 3,6-dialkyl-5,6-dihydro-4-hydroxy-2H-pyran-2-on
BR0012771A (pt) Processo para preparar uma composição de esterquat
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
EP2036920A4 (en) CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
PT1512679E (pt) Novos derivados de adamantano com actividades neuroprotectoras, anti-depressivas e anti-isquémicas e processo para os preparar
BR0314216A (pt) Processo para a produção de uma composição combustìvel
TW200502695A (en) Basic compound, resist composition and patterning process
WO2008035228A3 (en) 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
ATE387426T1 (de) Verfahren zur herstellung von shogaol und zwischenprodukte für dessen synthese
ITMI20050833A1 (it) Nuovo procedimento per la sintesi di aminoadamantani
TW200504113A (en) Curable polycyclic compounds and process for the production thereof
AR044320A1 (es) Derivados 3-decladinosilo de la clase de 9a - n-carbamoil - y 9a-ntiocarbamoil- 9 dihidro-9a aza- 9a - homoeritromicina a